Search Results 161-170 of 17282 for protein intake optimization

  1. A Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... requirements of the study. Prior ... protein (GAP) that negatively regulates p21-RAS signaling.

  2. Metastatic (stage 4) prostate cancer - Diagnosis and treatment - Mayo Clinic

    The protein is called prostate-specific membrane antigen. ... Radiopharmaceutical treatments can target a protein ... Admissions Requirements · Degree Programs.

  3. Pazopanib Hydrochloride in Treating Patients with Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Urine protein/creatinine ratio ≤ 1 OR 24-hour urine < 1 gram ... requirement for intravenous (IV) ...

  4. A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Ability to comply with all study requirements. ... * Clinical diagnosis of AS confirmed by a molecular ...

  5. Food allergy - Diagnosis and treatment - Mayo Clinic

    For people with food allergies, symptoms can range from annoying to life-threatening. Learn about diagnosis and treatment of this common immune reaction.

  6. Infectious Diseases! Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess levels of caffeine intake ... optimal protective potential of the ... protein antibodies, and to identify microRNA ...

  7. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... UPC < 1 or, if UPC ≥ 1, 24-hour urine protein ... requirements. Corrected QT interval (QTc) > 480 ...

  8. Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia - Mayo Clinic

    ... optimal dosages and risks/benefits. ... requirements for human studies must be met. Exclusion Criteria: Patients with Philadelphia chromosome positive/breakpoint ...

  9. Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Serum M-protein ≥ 0.5 g/dL; OR; Urine M-protein ... Be willing and able to comply with the study schedule and ...

  10. A Study to Evaluate the Safety and Effectiveness of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma Patients - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... protein 4 [CTLA-4], OX-40, CD137) - Has received ... participant's ability to cooperate with the requirements ...